Gainers
VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-market session. The company's market cap stands at $22.4 million.
WORK Medical Tech Gr (NASDAQ:WOK) sharesread more...
Gainers
VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-market session. The company's market cap stands at $22.4 million.
WORK Medical Tech Gr (NASDAQ:WOK) sharesread more...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE...
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether VYNE...
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE...
Direxion Daily TSLA Bear 1X Shares, Canopy Growth, VYNE Therapeutics, Better Choice, Rezolve AI, Bitfarms, and iRobot are the seven Penny stocks to watch today, according to MarketBeat's stock...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion...
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?